EVALUATION OF ACC RECURRENCES FOLLOWING DISCONTINUATION OF ADJUVANT MITOTANE THERAPY

M. Terzolo & M. Fassnacht

The primary aim of the study is to assess Tumor Free Survival after discontinuation of adjuvant mitotane treatment in patients with ACC who were disease-free at the time mitotane was stopped.

Main Inclusion Criteria

- Age ≥ 18 years
- Histologically confirmed diagnosis of ACC
- Stage I-III ACC (ENS@T staging system)
- Microscopically complete resection (R0)
- Patients with RX status are eligible if they are free of disease for at least 6 months.
- Duration of adjuvant mitotane treatment ≥ 12 mos
- Patient disease-free at the time of discontinuation of mitotane
- Follow-up duration until documented progression or at least 6 months following mitotane discontinuation

Patient data

- 126 patients from 11 centers
- 20 recurrences
- 3 deaths
- Median duration of mitotane treatment: 36 months (33 in the patients with recurrence, 39 in patients without)
- Median time from mitotane stop to recurrence: 11 months